Pathological aggregation of tau is a hallmark of Alzheimer’s disease and related tauopathies. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
43/100
A major barrier to research on Parkinson's disease is inaccessibility of diseased tissue for study. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD) and prion diseases, deposits of aggregated disease-specific proteins are found. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Chaperones are central to the proteostasis network (PN) and safeguard the proteome from misfolding, aggregation, and proteotoxicity. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
43/100
Few ill health situations are more degrading to people of any age than loss of reasoning, faculties, and personhood. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Caregivers were on average 64 years old, 72% female, and 49% were the spouse of the patient (32% wives, 17% husbands). 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
43/100
NPI total score significantly decreased in the experimental group at 8th, 16th, and 20th weeks (interaction time x group: F3,165=5.06, P=0.002). 4 key findings →
Participants: 30 Evidence: low
Full summary, score breakdown and related studies → Original source
Twenty-three elderly patients were found to have a consistent pattern of leukoencephalopathy by computed tomography and nuclear magnetic resonance imaging. 1 key finding →
Participants: 15 Evidence: low
Full summary, score breakdown and related studies → Original source
The authors blindly reviewed the charts of 20 patients with normal-pressure hydrocephalus (a disease of unknown cause characterized radiologically as chronic communicating hydrocephalus and clinically by gait apraxia, dementia, and incontinence) who had undergone creation of a ventriculoperitoneal shunt. 2 key findings →
Participants: 20 Evidence: low
Full summary, score breakdown and related studies → Original source
Gait was improved in 25 (72%) of the 35 patients, whereas the Bartel index remained unchanged. 5 key findings →
Participants: 29 Evidence: low
Full summary, score breakdown and related studies → Original source
We developed a set of informant-based items describing performance of activities of daily living (ADL) by patients with Alzheimer's disease (AD) to identify which ADL are useful for assessment of patients in clinical trials. 5 key findings →
Participants: 45 Evidence: low
Full summary, score breakdown and related studies → Original source
Donanemab was generally well tolerated up to 10 mg/kg. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Ranolazine and metformin may be frequently co‐administered in subjects with chronic angina and co‐morbid type 2 diabetes mellitus (T2DM). 2 key findings →
Design: clinical trial Participants: 28 Evidence: low
Full summary, score breakdown and related studies → Original source
Although the cause and the cure for dementia remain unknown, it is clear that environmental factors can offer relief of cognitive impairment and encourage emotional stability. 1 key finding →
Participants: 23 Evidence: low
Full summary, score breakdown and related studies → Original source
Our main findings support that the UPS pathway may be impaired in AD, and UCH-L1 may serve as an additional CSF biomarker for AD. 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
The clinical diagnosis of sporadic Creutzfeldt-Jakob disease (sCJD) is difficult, and reliable markers are highly desired. 2 key findings →
Participants: 71 Evidence: low
Full summary, score breakdown and related studies → Original source
Vascular dementia (VD) is the second most common dementia syndrome worldwide, and effective treatments are lacking. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Lecanemab is a humanized immunoglobulin G1 monoclonal antibody that selectively binds to soluble Aβ aggregate species, while demonstrating low affinity for Aβ monomer. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Oral infection with F. nucleatum could contribute to abnormalities in cognitive ability and pathological change in the brain of AD-like rats, which may be related to abnormal gut microbiota composition. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In aging, mitochondrial dysfunction may play a vital role in AD pathological changes and neuroinflammation. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Reference intervals for plasma biomarkers of AD may assist clinicians in making accurate clinical decisions. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
There is increasing evidence of the relationship between sleep and neurodegeneration, but this knowledge is not incorporated into clinical practice yet. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
CSF biomarkers measured with the LUMIPULSE system showed good agreement with amyloid PET imaging. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
HIV-associated neurocognitive disorders (HAND) is a term used to describe a variety of neurological impairments observed in HIV-infected individuals. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The dorsal PCC and retrosplenial cortex may have special importance in the pathogenesis and cognitive findings of AD. 5 key findings →
Participants: 21 Evidence: low
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →